ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
John S. Driscoll, 90, of Rockville, Maryland, died April 4, 2025.
“John started at Monsanto before joining the National Cancer Institute for a 30-year career. He designed novel brain antitumor agents based on the platform of the antiepileptic drug 5,5-diphenylhydantoin (Dilantin). During the HIV/AIDS pandemic, he discovered important 2′,3′-dideoxynucleosides. He published 150 scientific articles and the 2002 book Antiviral Drugs, and he was granted 20 US patents. John loved tennis and was a loyal friend and devoted family man. In the lab, he was a leader and a generous mentor, and he leaves an enduring mark on cancer research and on the many scientists he guided.”—Victor Marquez, colleague
Most recent title: Chief of the Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health
Education: BS, chemistry, Michigan State University, 1956; PhD, chemistry, Princeton University, 1960
Survivors: Wife, Katherine B. Driscoll; children, John N. Driscoll, Margaret Fitzgerald, and Laura Kane; five grandchildren
This remembrance has been edited for length, clarity, and style. To recognize your late loved one or colleague, submit obituary information at cenm.ag/obits.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X